|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02348 DAWNRAYS PHARMA
Nominal 
1.230 0.000 (0.000%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Turnover | 630,424 | 9.174% | 577,447 | 649,920 | 623,478 | 608,589 |
| Cost of Sales | (316,446) | 32.108% | (239,535) | (288,071) | (231,200) | (235,498) |
| Gross Profit | 313,978 | -7.083% | 337,912 | 361,849 | 392,278 | 373,091 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | (3,696) | (20,298) | (20,493) | (17,122) | |
| Profit / (Loss) before Taxation | 130,317 | -76.593% | 556,752 | 327,211 | 225,591 | 211,082 | |
| Taxation | (28,609) | -56.100% | (65,169) | (73,041) | (53,765) | (45,391) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 2,864 | 95.762% | 1,463 | 1,771 | (165) | 955 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 104,572 | -78.791% | 493,046 | 255,941 | 171,661 | 166,646 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (16,335) | 27.239% | (12,838) | (10,113) | (8,792) | (9,446) |
| Depreciation & Amortisation | 39,691 | -5.200% | 41,868 | 36,990 | 24,025 | 25,431 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| EPS (cts) | 6.961 | -78.816% | 32.860 | 17.070 | 11.456 | 11.127 |
| DPS (cts) | 1.366 | -- | 1.369 | 1.374 | 1.319 | 1.249 |
| Dividend Payout Ratio (%) | 19.623% | -- | 4.166% | 8.049% | 11.510% | 11.227% |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 2.198 | -- | 2.178 | 1.872 | 1.650 | 1.474 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 104,572 |
| %Change | -78.791% |
| EPS / (LPS) | RMB 0.070 |
| NBV Per Share (¥) | RMB 2.198 |